HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC And Cosmetics R&D Drive Dr Wolff’s 2019 Success

Executive Summary

Alpecin hair-loss shampoo manufacturer Dr Wolff achieved positive results in OTC and cosmetics categories in 2019 from increased R&D investment. 

You may also be interested in...



New CEO Signals ‘New Era’ For Germany’s Wörwag Pharma

Germany's Wörwag Pharma enters "new era" with the appointment of former P&G exec Jochen Schlindwein as its new CEO.

German Pharmaceutical Industry Associations Plan To Merge

Most German pharmaceutical companies will be represented by a new industry association if the proposed merger of the BAH and BPI in mid-2020 goes ahead.

UK Ad Authority Gives Caffeinated Shampoo Maker A Wakeup Call

Dr. Kurt Wolff’s study data for Alpecin Caffeine Shampoo is insufficient to support statements about hair-loss reduction, according to the Advertising Standards Authority’s March 28 ruling.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149574

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel